Abstract
The significance of the association between the appearance of hypopigmentation in patients with melanoma and the prognosis is still not clear. It was postulated that, in melanoma, an immune response is responsible for the destruction of the malignant as well as the normal pigmented cells, and that the eventual development of vitiligo-like patches in melanoma patients improves their prognosis. We studied the level of anti-melanoma antibodies in the sera of patients with melanoma with hypopigmentation and compared it to the titer in patients with melanoma only, to the titer of patients with vitiligo, and to that of healthy subjects. Only IgG-type antibodies were found in the sera of patients with vitiligo, with melanoma, or with melanoma with hypopigmentation. No significant differences in the titer of anti-melanoma antibodies could be found between the patients with melanoma when subgrouped according to the initial stage and the status of the disease at the time when the test was carried out. Statistically significantly (P<0.001) higher titers of antibodies were detected in the sera of patients with vitiligo in comparison to the lower titers in the other groups. Our results point to a similar immunobiological status, which probably does not give any advantage to patients with melanoma with hypopigmentation compared to patients without it. The appearance of hypopigmentary plaques in melanoma patients should be regarded, in our opinion, as a concomitant immunological phenomenon of the disease.
Similar content being viewed by others
References
Alexander MA, Lee W, Guerry D (1991) Retroviral vector transfection of a class II positive human metastatic melanoma cell line with a matched HLA-DR beta-1 gene restores its capacity to present antigens. Proc Annu Meet Am Assoc Cancer R32:1413A
Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A22-restricted cytotoxic T cell clones from melanoma patients. J Exp Me77:989
Betterle C, Del Prete GF, Peserico A, Bersani G, Caracciolo F, Trisotto A, Poggi F (1976) Autoantibodies in vitiligo. Arch Dermatol 112: 1328
Brostoff J, Bor S, Feiwel M (1969) Autoantibodies in patients with vitiligo. Lancet 11: 177
Bystryn JC (1989) Serum antibodies in vitiligo patients. Clin Dermatol 7: 136
Bystryn JC, Naughton GK (1984) Immunity to pigmented cells in vitiligo and melanoma. Fed Proc 43: 1664
Bystryn JC, Naughton GK (1985) The significance of vitiligo antibodies. J Dermatol 12: 1
Bystryn JC, Rigel D, Friedman RJ, Kopf A (1987) The prognostic significance of of vitiligo in patients with melanoma. Arch Dermatol 123: 1053
Donaldson RC, Canaan SA, McLean R, Ackerman LV (1974) Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery 76: 771
Dunston GM, Halder RM (1990) Vitiligo is associated with HLA-DR4 in black patients: a preliminary report. Arch Dermatol 126: 56–60
Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Zigelman R, Chaitchik S, Floro S, Djaldetti M (1993) Vitiligo autoantibodies are effective against melanoma. Cancer (in press)
Foley LM, Lowe NJ, Mischelhoff E, Tiwari JL (1983) Association of HLA-DR4 with vitiligo. J Am Acad Dermatol 8: 39–42
Galbraith GMP, Miller D, Emerson DL (1988) Western Blot Analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunol Immunopathol 48: 317–324
Gupta RK, Morton DL (1991) Detection of 90KD glycoprotein antigen containing immune complexes in sera of melanoma patients using an enzyme immunoassay. FASEB J 5: A1355
Harning R, Cui J, Bystryn JC (1991) Realtion between the incidence and level of pigmented cell antibodies and disease activity in vitiligo. J Invest Dermatol 97: 1078
Hertz KC, Gazze LA, Charles AB, Kirkpatrick H, Karz SL (1977) Autoimmune vitiligo detection of antibodies to melanin producing cells. N Engl J Med 297: 634
Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA (1991) Common expression of melanoma tumor associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen. J Immunother 10: 153–164
Hornung MO, Krementz EXT (1974) Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery 75: 477
Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB (1983) Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 9: 696
Laucius JF, Mastrangelo MJ (1979) Cutaneous depigmentary phenomena in patients with malignant melanoma. In: Human malignant melanoma. Grunne & Straton, Philadelphia, p 209
Lerner AB, Cage CW (1973) Melanoma in horses. Yale J Biol Med 46: 650
Lerner AB, Nordlund J, (1977) Should vitiligo be induced in patients after resection of primary melanoma? Arch Dermatol 113: 421
Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Hamilton-Fairley G, Bodenham DC, Alexander P (1969) Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J 3: 547
Lewis MG, Phillips TM, Cook KB, Blake J (1971) Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma. Nature 232: 52
McBurney EL (1979) Vitiligo: clinical picture and pathogenesis. Arch Intern Med 139: 1295
Moellman GE, Krass P, Halaban R (1985) On the subject of serum antibodies to melanocytes in vitiligo. J Invest Dermatol 84: 333
Morton DL, Eilber RJ, Joseph WL, Wood EC, Traham E, Ketcham AS (1970) Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg 172: 740
Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF (1992) Prolongation of survival in metastatic melanoma after active specific immunization with a new polyvalent melanoma vaccine. Ann Surg 216: 463
Naughton G, Reggiardo D, Bystryn JC (1986) Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 15: 978
Nordlund JJ, Lerner AB (1982) Vitiligo: it is important. Arch Dermatol 118: 5
Nordlung JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9: 689
Old LJ, Stockert E, Boyse EA, Kim JH (1968) Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med 127: 523
Ortonne JP, Gauthier Y, Guillet G, Gauthier O (1978) Depigmentation cutanée associée au melanoma malin. Ann Dermatol Venerol 105: 1043
Shoenfeld Y, Isenberg D (1988) The mosaic of autoimmunity. Elsevier, Amsterdam, pp 1–550
Soubiran P, Benzaken S, Lellet C (1985) Vitiligo peripheral T cell subset imbalance as defined by monoclonal antibodies. Vr J Dermatol 113 [Suppl 28]: 124–125
Swissa M, Amital-Teplizki H, Haim N, Cohen Y, Shoenfeld Y (1990) Autoantibodies in neoplasia: an unresolved enigma. Cancer 65: 2554
Author information
Authors and Affiliations
Additional information
This work was supported by a grant given by the Israeli Chief Scientist, Ministry of Health, Israel
Rights and permissions
About this article
Cite this article
Merimsky, O., Shoenfeld, Y., Yecheskel, G. et al. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 38, 411–416 (1994). https://doi.org/10.1007/BF01517212
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01517212